What should I know about Novo Nordisk?
Neurocrine Biosciences is a US biopharmaceutical company, based in San Diego, California, that develops and sells medicines for neurological, psychiatric and endocrine disorders. It also works in immunological conditions. Its second-quarter 2026 results describe a company with three marketed products and a late-stage pipeline. It grew its portfolio in May 2026 by acquiring Soleno Therapeutics for about $2.9 billion in cash. Neurocrine discovers many of its own drugs in-house and sells them directly to patients' doctors in the United States. It is led by chief executive Kyle Gano and trades on the Nasdaq under the ticker NBIX.
What are Neurocrine Biosciences's main drugs?
Neurocrine's best-selling medicine is Ingrezza (valbenazine), used for movement disorders such as tardive dyskinesia. According to its Q2 2026 results, Ingrezza brought in $716 million in the quarter, up 15% on a year earlier. Crenessity (crinecerfont), a treatment for congenital adrenal hyperplasia, made $184 million. Vykat XR (diazoxide choline), acquired with Soleno and used for Prader-Willi syndrome, added $54 million from its May 2026 purchase date. The company raised its 2026 Ingrezza sales guidance to between $2.825 billion and $2.875 billion.
What is Neurocrine Biosciences currently developing?
Neurocrine's pipeline centres on psychiatry and endocrine conditions. Two programmes are in Phase 3: osavampator, for major depressive disorder, and direclidine, for schizophrenia. Readouts from both are expected in 2027, according to its Q2 2026 results. The company has also started a Phase 2 study of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia, a younger group than the drug's current approval covers. Neurocrine reported R&D spending guidance of $1.275 billion to $1.325 billion for 2026.
Is Neurocrine Biosciences publicly traded, and how big is it?
Yes. Neurocrine Biosciences trades on the Nasdaq under the ticker NBIX. Its market capitalisation was about $14.4 billion on 8 October 2026. Total revenue in the first half of 2026 was $1.77 billion, up from $1.26 billion in the same period of 2025, and second-quarter revenue was $959 million. Net product sales made up almost all of that.